Japanese year-end approvals include Eliquis, Ryzodeg and Cimzia
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's novel anticoagulant Eliquis (apixaban 2.5mg tablet) has been approved in Japan for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation, setting the stage for a market showdown with Bayer's Xarelto (rivaroxaban) and Boehringer Ingelheim's Prazaxa (dabigatran) in this setting.